{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:38:25Z","timestamp":1776836305843,"version":"3.51.2"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with chronic kidney disease exhibit a higher risk of developing malignancies, and among those with end-stage renal disease (ESRD) on dialysis, approximately 7% are diagnosed with new-onset tumors within five years. Patients with ESRD who are receiving antineoplastic treatment exhibit a significantly higher incidence and greater severity of adverse effects associated with antineoplastic agents compared to individuals with normal renal function. This complexity involves multiple factors, including the therapy options and dose adjustment of antineoplastic agents, drug-related toxicities, management of fluid overload, and the maintenance of internal homeostasis in ESRD patients with malignancies. Patients undergoing hemodialysis are at heightened risk of drug toxicity if doses of renally cleared medications are not appropriately individualized; conversely, subtherapeutic drug exposure may occur due to premature and substantial removal of medications during the dialysis session. Unfortunately, there is little information on the appropriate dosing and pharmacokinetics of most chemotherapeutic agents in dialysis patients being treated for cancer. Therefore, ensuring the safety of antineoplastic therapy in ESRD patients has emerged as a significant clinical challenge for both nephrologists and oncologists. This article summarized the effects of uremia and hemodialysis on the pharmacokinetics of commonly used antineoplastic agents, along with an overview of real-world evidence on the use of these agents in patients with ESRD undergoing hemodialysis. It aims to provide clinically valuable information to optimize antineoplastic therapy in this patient population, with the ultimate goal of prolonging survival periods and reducing the incidence of severe drug-related complications.<\/jats:p>","DOI":"10.3389\/fonc.2026.1777042","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:39:53Z","timestamp":1776832793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Ke","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-qing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-yuan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.ajkd.2022.02.020","article-title":"Cancer risk and mortality in patients with kidney disease: a population-based cohort study","volume":"80","author":"Kitchlu","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2023.2232046","article-title":"Cancer before and after the start of hemodialysis and association with mortality - an Eastern-European multicenter study","volume":"45","author":"Gadalean","year":"2023","journal-title":"Ren Fail"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac124","article-title":"The incidence of cancer recurrence and new cancer following commencement of dialysis","volume":"15","author":"Lim","year":"2022","journal-title":"Clin Kidney J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5171","article-title":"Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer","volume":"12","author":"Delaye","year":"2023","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2015.08.003","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101268","article-title":"Care for end-stage kidney disease in China: progress, challenges, and recommendations","volume":"54","author":"Chen","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000504243","article-title":"Incidence, risk, and prognosis of cancer in patients on chronic hemodialysis","volume":"49","author":"Chen","year":"2020","journal-title":"Blood Purif"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015040373","article-title":"Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2024.151494","article-title":"Epidemiology of cancer in kidney transplant recipients","volume":"44","author":"Massicotte-Azarniouch","year":"2024","journal-title":"Semin Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1038\/s41598-021-83164-6","article-title":"Epidemiological characteristics of cancers in patients with end-stage kidney disease: a Korean nationwide study","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-019-1283-4","article-title":"Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy","volume":"20","author":"Taborelli","year":"2019","journal-title":"BMC Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.11.013","article-title":"Gender and age differences of genitourinary cancers among chronic dialysis patients in Taiwan","volume":"20","author":"Tang","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.12969","article-title":"Paraneoplastic syndrome after kidney transplantation: frequency, risk factors, differences to paraneoplastic occurrence of glomerulonephritis in the native kidney, and implications on long-term kidney graft function","volume":"37","author":"Zakrocka","year":"2024","journal-title":"Transpl Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy175","article-title":"Chronic inflammation in end-stage renal disease and dialysis","volume":"33","author":"Cobo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2025.127343","article-title":"Do microplastics (MPs) and nanoplastics (NPs) directly contribute to human carcinogenesis","volume":"388","author":"Casella","year":"2026","journal-title":"Environ pollut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.868715","article-title":"Chronic kidney disease and cancer: inter-relationships and mechanisms","volume":"10","author":"Hu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102050","DOI":"10.1016\/j.clgc.2024.02.001","article-title":"Acquired cystic disease-associated renal cell carcinoma: a systematic review and meta-analysis","volume":"22","author":"Duong","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29338","article-title":"Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid","volume":"136","author":"Jelakovi\u0107","year":"2015","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15880","article-title":"Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: a longitudinal cohort analysis from northern India","volume":"37","author":"Ranjan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.03.010","article-title":"Cancer mortality in people receiving dialysis for kidney failure: an Australian and New Zealand cohort study, 1980-2013","volume":"80","author":"Rosales","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/01.asn.0000039608.81046.81","article-title":"Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand","volume":"14","author":"Stewart","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000301","article-title":"Chemotherapy in cancer patients undergoing hemodialysis: a nationwide study in Japan","volume":"3","author":"Funakoshi","year":"2018","journal-title":"ESMO Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199903)32:3<177::aid-mpo3>3.0.co;2-h","article-title":"Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients","volume":"32","author":"Rossi","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","article-title":"Electrolyte disorders associated with the use of anticancer drugs","volume":"777","author":"Liamis","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.04.005","article-title":"Hyponatremia--SIADH in lung cancer diagnostic and treatment algorithms","volume":"96","author":"Groh\u00e9","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4158\/ep.11.4.254","article-title":"Hypocalcemia and parathyroid function in metastatic prostate cancer","volume":"11","author":"Tandon","year":"2005","journal-title":"Endocr Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells13121051","article-title":"Hypercalcemia in cancer: causes, effects, and treatment strategies","volume":"13","author":"Bartkiewicz","year":"2024","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0267","article-title":"Lactic acidosis in patients with solid cancer","volume":"37","author":"Heneberg","year":"2022","journal-title":"Antioxid Redox Signal"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1042\/cs103s035s","article-title":"Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumor cell lines of different origin: expression and effects on proliferation","volume":"103","author":"Takahashi","year":"2002","journal-title":"Clin Sci Lond"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1488853","article-title":"Comprehensive analysis of VEGF\/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/life14070865","article-title":"Cancer-associated thrombotic microangiopathy: literature review and report of five cases","volume":"14","author":"Posado-Dom\u00ednguez","year":"2024","journal-title":"Life Bsl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac213","article-title":"Retrospective study of 59 cases of cancer-associated thrombotic microangiopathy: presentation and treatment characteristics","volume":"38","author":"Decaestecker","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1382.e1","DOI":"10.1016\/j.amjmed.2018.04.025","article-title":"Tramadol: understanding the risk of serotonin syndrome and seizures","volume":"131","author":"Hassamal","year":"2018","journal-title":"Am J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.11.011","article-title":"International trends in cancer incidence in middle-aged and older adults in 44 countries","volume":"13","author":"Pilleron","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12972","article-title":"Drug dosing considerations in continuous renal replacement therapy","volume":"34","author":"Jang","year":"2021","journal-title":"Semin Dial"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/bf03190876","article-title":"The role of the protein-binding on the mode of drug action as well the interactions with other drugs","volume":"33","author":"Tesseromatis","year":"2008","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000086591","article-title":"FHD: an index to evaluate drug elimination by hemodialysis","volume":"25","author":"Launay-Vacher","year":"2005","journal-title":"Am J Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.13020","article-title":"Treatment of advanced ovarian cancer with carboplatin and paclitaxel in a patient undergoing hemodialysis: case report and literature review","volume":"26","author":"Yang","year":"2022","journal-title":"Hemodial Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.02.007","article-title":"Carboplatin therapeutic drug monitoring in intermittent hemodialysis-a case report and review of the literature","volume":"47","author":"Bucher","year":"2025","journal-title":"Clin Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1002\/phar.1354","article-title":"Carboplatin pharmacokinetics in a patient receiving hemodialysis","volume":"34","author":"Fong","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2139\/ssrn.4082293","article-title":"Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: a multicenter retrospective cohort study (NEJ-042)","volume":"172","author":"Minegishi","year":"2022","journal-title":"Lung Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000167","article-title":"Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societ\u00e0 Italiana di Nefrologia (SIN)","volume":"2","author":"Pedrazzoli","year":"2017","journal-title":"ESMO Open"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13256-017-1213-7","article-title":"Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report","volume":"11","author":"Hirakawa","year":"2017","journal-title":"J Med Case Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/1120009x.2020.1728861","article-title":"Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer","volume":"33","author":"Maruta","year":"2021","journal-title":"J Chemother"},{"key":"B47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","article-title":"Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management","volume":"80","author":"Oronsky","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100698","article-title":"Self-assembly nanoplatform of platinum (IV) prodrug for enhanced ovarian cancer therapy","volume":"21","author":"Ma","year":"2023","journal-title":"Mater Today Bio"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0b013e32811d69cb","article-title":"Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under hemodialysis for chronic renal dysfunction: two cases considered","volume":"18","author":"V\u00e9nat-Bouvet","year":"2007","journal-title":"Anticancer Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000055204","article-title":"Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure","volume":"25","author":"Stemmler","year":"2002","journal-title":"Onkologie"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/030089161109700221","article-title":"Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer","volume":"97","author":"Huang","year":"2011","journal-title":"Tumori"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199039030-00008","article-title":"Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer","volume":"39","author":"Henwood","year":"1990","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sj.bjc.6600687","article-title":"Feasibility of combination chemotherapy with cisplatin and etoposide for hemodialysis patients with lung cancer","volume":"88","author":"Watanabe","year":"2003","journal-title":"Br J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04577-w","article-title":"Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure","volume":"93","author":"Imamaki","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034x.2008.00448.x","article-title":"Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient","volume":"39","author":"Katamura","year":"2009","journal-title":"Hepatol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy012","article-title":"Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient","volume":"11","author":"Yeung","year":"2018","journal-title":"Clin Kidney J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.11405\/nisshoshi.112.287","article-title":"Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis","volume":"112","author":"Iida","year":"2015","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.5414\/cn109327","article-title":"Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review","volume":"90","author":"Hann","year":"2018","journal-title":"Clin Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210390255","article-title":"A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL\/min) and end stage renal disease on hemodialysis","volume":"18","author":"Jhaveri","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13557","article-title":"Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2\u2019,2\u2019-difluorodeoxyuridine and their nucleotides","volume":"84","author":"Derissen","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0574-3","article-title":"Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment","volume":"51","author":"Kiani","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01478-4","article-title":"Chemotherapy with gemcitabine for unresectable intrahepatic cholangiocarcinoma in a patient undergoing maintenance hemodialysis","volume":"14","author":"Matsumoto","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3892\/ol.2024.14661","article-title":"Effective treatment of collecting duct carcinoma in a recipient of a kidney transplant: A case report","volume":"28","author":"Nascimento de Assis","year":"2024","journal-title":"Oncol Lett"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01413-8","article-title":"Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. A cost-effectiveness analysis","volume":"45","author":"Abushanab","year":"2025","journal-title":"Clin Drug Investig"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","volume":"88","author":"Gaible","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000186882","article-title":"Vinorelbine therapy in a hemodialyzed patient","volume":"61","author":"Rollino","year":"1992","journal-title":"Nephron"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2021.01.044","article-title":"Favorable survival with combined treatment in a metastatic breast cancer patient undergoing hemodialysis: A case report","volume":"79","author":"Matsumoto","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01048.x","article-title":"High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature","volume":"18","author":"Baur","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1186\/s12885-015-1932-3","article-title":"Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report","volume":"15","author":"Yang","year":"2015","journal-title":"BMC Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000359","article-title":"Drug-coated balloon angioplasty for dysfunctional arteriovenous hemodialysis fistulae: A randomized controlled trial","volume":"19","author":"Zhao","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-249474","article-title":"Gestational trophoblastic neoplasm in a patient with end-stage renal failure (ESRF): the challenges and lessons learnt","volume":"15","author":"Loo","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100067","article-title":"Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer","volume":"81","author":"Hunz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/bf00686499","article-title":"Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis","volume":"33","author":"Yoshida","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl498","article-title":"Pharmacokinetic analysis of docetaxel during hemodialysis in a patient with locally advanced non-small cell lung cancer","volume":"22","author":"Hochegger","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095033","article-title":"Albumin binds doxorubicin via self-assembling dyes as specific polymolecular ligands","volume":"23","author":"Jagusiak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14933","article-title":"Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review","volume":"112","author":"Yasuda","year":"2021","journal-title":"Cancer Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"575629","DOI":"10.1155\/2009\/575629","article-title":"Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis","volume":"2009","author":"Carlson","year":"2009","journal-title":"Sarcoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04514-x","article-title":"Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis","volume":"91","author":"Baum","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/ndt\/gfl664","article-title":"Pharmacokinetics of bevacizumab in hemodialysis","volume":"22","author":"Garnier-Viougeat","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2020.05.001","article-title":"Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review","volume":"47","author":"Klajer","year":"2020","journal-title":"Semin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.01.004","article-title":"Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience","volume":"12","author":"Shetty","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14436","article-title":"International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis","volume":"40","author":"D\u00edaz-Gonz\u00e1lez","year":"2020","journal-title":"Liver Int"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyr015","article-title":"Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center","volume":"41","author":"Kennoki","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn626","article-title":"Pharmacokinetics of sunitinib in hemodialysis","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.714","article-title":"Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib","volume":"56","author":"Nguyen","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-014-9611-1","article-title":"A case report\u2014Treatment of metastatic colorectal cancer in a patient on hemodialysis","volume":"45","author":"Bolonesi","year":"2014","journal-title":"J gastrointestinal Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8365-21","article-title":"Thrombotic microangiopathy, podocytopathy, and damage to the renal tubules with severe proteinuria and acute renal dysfunction induced by lenvatinib","volume":"61","author":"Nakashima","year":"2022","journal-title":"Intern Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053215","article-title":"Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance","volume":"41","author":"Shen","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12537","article-title":"Hypertension induced by tyrosine-kinase inhibitors for the treatment of renal cell carcinoma in hemodialysis patients: A single-center experience and review of the literature","volume":"21","author":"Nakai","year":"2017","journal-title":"Ther Apher Dial"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.112","article-title":"Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience","volume":"11","author":"Czarnecka","year":"2015","journal-title":"Future Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i19.6360","article-title":"Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis","volume":"10","author":"Lan","year":"2022","journal-title":"World J Clin cases"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3201-9","article-title":"Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis","volume":"79","author":"Imai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28494","article-title":"Hemodialysis and imatinib: Plasma levels, efficacy and tolerability in a patient with metastatic GIST - Case report","volume":"10","author":"De Luca","year":"2024","journal-title":"Heliyon"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.6709","article-title":"A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate","volume":"51","author":"Wada","year":"2012","journal-title":"Intern Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.08.018","article-title":"Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series","volume":"31","author":"Lunardi","year":"2009","journal-title":"Clin Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12390","article-title":"Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases","volume":"20","author":"Omae","year":"2016","journal-title":"Hemodial Int"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0492-7","article-title":"Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis","volume":"18","author":"Miyake","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"100314","DOI":"10.1016\/j.ctarc.2021.100314","article-title":"Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure","volume":"27","author":"Gonz\u00e1lez","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211003641","article-title":"Trastuzumab and pertuzumab in hemodialysis: A case report","volume":"27","author":"Gaertner","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1430","article-title":"Pharmacokinetics of lapatinib, a nonrenally cleared drug, in patients with end-stage renal disease on maintenance hemodialysis","volume":"59","author":"Pai","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14309\/00000434-201510001-01221","article-title":"Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing hemodialysis","volume":"30","author":"Park","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15298","article-title":"Efficacy and safety of full-dose dabrafenib and trametinib combination therapy in a patient on hemodialysis with metastatic melanoma","volume":"60","author":"Hayakawa","year":"2021","journal-title":"Int J Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-581","article-title":"Safety and efficacy of vemurafenib in end stage renal failure","volume":"13","author":"Iddawela","year":"2013","journal-title":"BMC Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04163-4","article-title":"Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function","volume":"86","author":"Yu","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01564-1","article-title":"Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report","volume":"43","author":"Takakura","year":"2025","journal-title":"Invest New Drugs"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1081\/jdi-48241","article-title":"Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis","volume":"27","author":"Heilberg","year":"2005","journal-title":"Ren Fail"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9243-7","article-title":"Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis","volume":"100","author":"Langenegger","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"B112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.jrn.2009.08.005","article-title":"Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia","volume":"20","author":"Yeh","year":"2010","journal-title":"J Ren Nutr"},{"key":"B113","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B115","unstructured":"Highlights of prescribing Opdivo (Nivolumab). FDA guidelines"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.04.004","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers","volume":"17","author":"Tachibana","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab185","article-title":"Blood-incompatibility in hemodialysis: alleviating inflammation and effects of coagulation","volume":"14","author":"Bowry","year":"2021","journal-title":"Clin Kidney J"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J Transl Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000243","article-title":"Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy","volume":"41","author":"Liu","year":"2018","journal-title":"J Immunother"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5124","article-title":"High-throughput liquid chromatography\/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma","volume":"35","author":"Hirasawa","year":"2021","journal-title":"BioMed Chromatogr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1777042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:40:17Z","timestamp":1776832817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1777042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":129,"alternative-id":["10.3389\/fonc.2026.1777042"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1777042","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1777042"}}